Printer Friendly

US FDA Grants Orphan Drug Designation for NantCell's Ganitumab Monoclonal Antibody Therapy in Ewing Sarcoma.

M2 PHARMA-April 11, 2017-US FDA Grants Orphan Drug Designation for NantCell's Ganitumab Monoclonal Antibody Therapy in Ewing Sarcoma


- The US FDA has granted Orphan Drug Designation to US-based immuno-oncology company NantCell, Inc's Ganitumab, Insulin Growth Factor-1R (IGF-1R) monoclonal antibody therapy for the treatment of patients with Ewing sarcoma, the company said.

Ganitumab is a fully human monoclonal antibody directed against IGF-1R that is being investigated in a Phase III human clinical trial titled "Combination Chemotherapy with or without Ganitumab in Treating Patients with Newly Diagnosed Metastatic Ewing Sarcoma" (NCT02306161) by the National Cancer Institute in partnership with Children's Oncology Group and NantCell at clinical sites across the United States and Canada.

IGF-1R plays a role in the development and progression of many cancers, possibly due to its anti-apoptotic properties, which allow cancerous cells to resist the cytotoxic properties of chemotherapeutic drugs or radiation therapy.

Ganitumab inhibits cancer cell proliferation through disruption of the P13K/Akt and MAPK pathways. Signaling through IGF-1R plays an important role in the regulation of cell growth and survival, and has been shown to be a critical promoter of anchorage independent growth, a well-recognized mechanism for malignancy.

NantCell, a wholly-owned subsidiary of NantWorks, LLC, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by developing molecularly targeted therapeutics, based on the proteomic profile of the patient's tumor, independent of the cancer's anatomical type.

The company's mission is to make obsolete the standard method of clinical trial design of "trial and error" and replace it with a level of quantitative predictability based on both the genomic and proteomic profile performed a priori.

NantCell will tap into comprehensive "omic" analytic tools and "big data" generated from supercomputing to develop molecularly designed drugs in this era of genomics and proteomics and identify patients and their tumor signature at the most granular cellular, DNA and protein levels.

Patients entering clinical trials would be identified after a comprehensive "omic" analysis from tissue to cell to DNA to RNA to protein to peptide to drug, and tested based on this molecular profile to maximize clinical outcome and minimise side effects.

Through these integrated diagnostic methods, the company is pursuing the vision of treating the biology of cancer rather than the anatomy, and drive the immune system inherited by all to defeat cancer.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 11, 2017
Previous Article:NuGEN Technologies Launches Two New RNA-Seq Kits for High Sensitivity Transcriptomics.
Next Article:InVivo Therapeutics Adds Site for INSPIRE Study.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters